Latest

5 stories

Hide weekly roundups

Yesterday

Takeda posts results for TAK-881 vs HYQVIA pharmacokinetic study in PIDD patients

Trial updateTakeda Pharmaceutical Co Ltd

Friday, September 25

Takeda terminates GDX012 AML trial by sponsor decision; results posted

Trial updateTakeda Pharmaceutical Co Ltd

Wednesday, August 26

Takeda's GATTEX gets REMS-related supplement approved by FDA

Regulatory decisionTakeda Pharmaceutical Co Ltd teduglutide

Tuesday, August 11

Takeda gets FDA labeling approvals for Actoplus Met and Kazano

Weekly roundup, 2 itemsalogliptin and metformin hydrochloride pioglitazone and metformin hydrochloride

Wednesday, August 5

Regulatory decisionoveporexton Takeda Pharmaceutical Co Ltd

FDA approves Takeda's Orzeyful for new molecular entity application

The agency's records show a submission status date of August 5, 2026, with an approval letter dated August 6, 2026.

Drugs@FDA